<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158795</url>
  </required_header>
  <id_info>
    <org_study_id>104124</org_study_id>
    <nct_id>NCT00158795</nct_id>
  </id_info>
  <brief_title>Assess Safety &amp; Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine</brief_title>
  <official_title>Assess the Safety &amp; Reactogenicity of GSK Biologicals Hib Vaccine Co-administered With Chinese Local DTPw Vaccine When Compared to Chinese Local DTPw Vaccine Administered Alone, in Healthy Infants at 3,4 &amp; 5 Mths of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To assess safety and reactogenicity of GSK Biologicals' Haemophilus influenza type b vaccine
      co-administered with or without Chinese DTPw vaccine administered alone in healthy infants
      (3, 4 and 5 months of age)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be randomized into two groups. One group will receive DTPw vaccine
      co-administered with Hib and another group will receive DTPw vaccine alone. A specific
      follow-up of solicited local and general symptoms after each vaccination. A specific
      follow-up of unsolicited symptoms after each vaccination. Recording of serious adverse events
      reported during the study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited symptoms of grade 3 intensity, during the specific follow-up period after vaccination.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Occurrence of solicited symptoms during the specific follow up period after vaccination.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Occurrence of unsolicited symptoms during the specific follow up period after vaccination.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Occurrence of serious adverse events during the study period.</measure>
  </secondary_outcome>
  <enrollment type="Actual">454</enrollment>
  <condition>Haemophilus Influenzae Type b Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemophilus Influenza type b vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female infant between, and including, 11 and 17 weeks of age at the time of
             the first vaccination.

        Exclusion Criteria:

          -  Planned administration of a vaccine not foreseen by the study protocol during the
             period starting 30 days before the administration of the first vaccine dose and ending
             30 days after the last dose.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs from
             birth until administration of first dose of study vaccine.

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the first dose of study vaccine, or planned use during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

